EUCTR2009-010730-21-ES进行中（未招募）不适用
A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric CancerEstudio de fase 2, abierto, de evaluación de la eficacia y la seguridad de telatinib en combinación con quimioterapia como tratamiento de primera línea en pacientes con cáncer gástrico avanzado
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age > 18 years
- •2. Histologically or cytologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction with inoperable locally advanced or metastatic disease, not amenable to curative therapy
- •3. At least 1 measurable lesion that has not been irradiated. The lesion will be measured according to Response Evaluation Criteria in Solid Tumors (RECIST), and be documented by radiological evaluation within 28 days prior to study entry
- •(4. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 at study entry
- •5. Prior radiation therapy completed at least 28 days prior to study entry (if applicable)
- •6. Adequate bone marrow, liver, and renal function at study entry as assessed by:
- •? Hemoglobin > 9.0 g/dL (transfusion and growth factor independent)
- •? Platelet count > 100,000/µL (transfusion independent)
- •? Absolute neutrophil count (ANC) > 1500/µL (growth
- •factor independent)
- •? Total bilirubin < 2.0 times the upper limit of normal
- •? Alanine aminotransferase (ALT [SGPT]) and aspartate aminotransferase (AST [SGOT]) < 5.0 x ULN in the presence of liver metastasis; ALT [SGPT] and AST [SGOT] < 2.5 x ULN in the absence of liver
- •? International normalized ratio for prothrombin time
- •(PT-INR) < 1.5 and activated partial thromboplastin
- •time (aPTT) < 1.5 x ULN. The use of full-dose oral or
- •parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the subject has been on a stable dose of anticoagulants for at least two weeks before study entry.
- •? Serum creatinine < 1.5 times ULN
- •? Calculated creatinine clearance > 60 mL/min. The
- •Cockroft and Gault formula (Section 12.7) is
- •recommended for calculation of creatinine clearance.
- •Subjects with a calculated creatinine clearance below 60 mL/min may be eligible if a measured creatinine
- •clearance (based on 24 hour urine collection or other
- •reliable method) is > 60 mL/min
- •7. Negative serum pregnancy test performed within 7 days prior to study entry for women of childbearing potential
- •8. Women and men of childbearing potential must agree to use adequate contraception (e.g., condom, intrauterine device (IUD), oral contraceptive, or double-barrier method), prior to study entry, for the duration of study participation and 28 days
- •after the last study drug dosing
- •9. Able and willing to sign a written informed consent. A signed informed consent must be appropriately obtained prior to any study specific procedures.
- •10. Able to comply with study procedures and follow-up examinations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous chemotherapy for locally advanced or metastatic gastric cancer. Subjects may have received prior neoadjuvant or adjuvant chemotherapy as long as it was completed at least
- •6 months prior to study entry.
- •2. Previous anti-angiogenic therapy (i.e. anti-VEGF or VEGFR tyrosine kinase inhibitor such as bevacizumab, sorafenib,sunitinib, AZD2171)
- •3. Previous total platinum dose >300 mg/m2 [Total prior platinum dose of <300 mg/m2 will be allowed in the adjuvant or neo-adjuvant setting as long as it was completed at least 6 months prior to study entry]
- •4. Locally advanced disease that is amenable to curative therapy (including operation and/or chemotherapy and/or radiotherapy)
- •5. Clinical or radiographic evidence of brain metastasis
- •6. Cardiac disease defined by:
- •? Congestive heart failure > class II New York Heart
- •Association (NYHA) (Section 12.5), or
- •? Unstable angina (anginal symptoms at rest), or newonset angina (began within the last 12 months), or myocardial infarction within the 12 months prior to
- •enrolment, or
- •? Cardiac ventricular arrhythmias requiring antiarrhythmic therapy
- •? Atrial fibrillation or atrioventricular heart block
- •7. Uncontrolled hypertension at study entry (systolic blood pressure >150 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management
- •8. Any (including pulmonary) hemorrhage/bleeding event > grade 3 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.3.0 within 28 days prior to study entry
- •9. Major surgery, open biopsy, or significant traumatic injury within 28 days prior to study entry
- •10. Current serious, non-healing wound, ulcer, or bone fracture at study entry
- •11. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study entry
- •12. Active clinically serious infection > grade 3 by NCI-CTCAE v.3.0 at study entry
- •13. Known human immunodeficiency virus (HIV) infection or chronic hepatitis B (HBV) or C (HCV). The safety of telatinib in this subject population has not been studied.
- •14. Previous or concurrent cancer that is distinct in primary site or histology from gastric cancer. Subjects with cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis) or any cancer curatively treated > 3 years
- •prior to study entry are eligible.
- •15. Anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy or tumor embolization) or investigational agent within 28 days prior to study entry
- •16. Known or suspected allergy to any component of telatinib, cisplatin or capecitabine
- •17. Known dihydropyrimidine dehydrogenase (DPD) deficiency
- •18. Unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions) that could affect oral intake of capecitabine and telatinib
- •19. Prior or current history of substance abuse, or medical, psychological, or social condition that in the opinion of the investigator may interfere with the subject?s participation in the study or evaluation of the study result
- •20. Women who are pregnant or breast-feeding
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate how safe and how effective is CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell LymphomaPatients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell LymphomaMedDRA version: 19.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004509-34-FRCuris, Inc.120
进行中（未招募）
1 期
Study to Evaluate how safe and how effective is CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC AlterationsPatients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma including patients with MYC alterationsMedDRA version: 19.1 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004509-34-NLCuris, Inc.200
撤回
2 期
Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC AlterationsLymphomaNL-OMON46260Curis, Inc.10
进行中（未招募）
1 期
Study to Evaluate how safe and how effective is CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell LymphomaPatients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell LymphomaMedDRA version: 19.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004509-34-ESCuris, Inc.120
进行中（未招募）
1 期
Study to Evaluate how safe and how effective is CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC AlterationsPatients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma including patients with MYC alterationsMedDRA version: 21.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004509-34-DECuris, Inc.200